These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 22736027)

  • 1. Metronomic chemotherapy in combination with antiangiogenic treatment induces mosaic vascular reduction and tumor growth inhibition in hepatocellular carcinoma xenografts.
    Zhou F; Hu J; Shao JH; Zou SB; Shen SL; Luo ZQ
    J Cancer Res Clin Oncol; 2012 Nov; 138(11):1879-90. PubMed ID: 22736027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma.
    Tang TC; Man S; Lee CR; Xu P; Kerbel RS
    Neoplasia; 2010 Mar; 12(3):264-74. PubMed ID: 20234820
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bevacizumab enhances chemosensitivity of hepatocellular carcinoma to adriamycin related to inhibition of survivin expression.
    Xiong YQ; Sun HC; Zhu XD; Zhang W; Zhuang PY; Zhang JB; Xu HX; Kong LQ; Wu WZ; Qin LX; Tang ZY
    J Cancer Res Clin Oncol; 2011 Mar; 137(3):505-12. PubMed ID: 20490863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of antiangiogenic therapy on tumor growth, vasculature and kinase activity in basal- and luminal-like breast cancer xenografts.
    Lindholm EM; Kristian A; Nalwoga H; Krüger K; Nygård S; Akslen LA; Mælandsmo GM; Engebraaten O
    Mol Oncol; 2012 Aug; 6(4):418-27. PubMed ID: 22521242
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease.
    Kerbel RS; Shaked Y
    Cancer Lett; 2017 Aug; 400():293-304. PubMed ID: 28202353
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antiangiogenic and antitumor activity of LP-261, a novel oral tubulin binding agent, alone and in combination with bevacizumab.
    Gardner ER; Kelly M; Springman E; Lee KJ; Li H; Moore W; Figg WD
    Invest New Drugs; 2012 Feb; 30(1):90-7. PubMed ID: 20820910
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bevacizumab and rapamycin induce growth suppression in mouse models of hepatocellular carcinoma.
    Huynh H; Chow PK; Palanisamy N; Salto-Tellez M; Goh BC; Lee CK; Somani A; Lee HS; Kalpana R; Yu K; Tan PH; Wu J; Soong R; Lee MH; Hor H; Soo KC; Toh HC; Tan P
    J Hepatol; 2008 Jul; 49(1):52-60. PubMed ID: 18490075
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.
    Wang C; Gao D; Guo K; Kang X; Jiang K; Sun C; Li Y; Sun L; Shu H; Jin G; Sun H; Wu W; Liu Y
    BMC Cancer; 2012 May; 12():166. PubMed ID: 22559167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dual Metronomic Chemotherapy with Nab-Paclitaxel and Topotecan Has Potent Antiangiogenic Activity in Ovarian Cancer.
    Previs RA; Armaiz-Pena GN; Lin YG; Davis AN; Pradeep S; Dalton HJ; Hansen JM; Merritt WM; Nick AM; Langley RR; Coleman RL; Sood AK
    Mol Cancer Ther; 2015 Dec; 14(12):2677-86. PubMed ID: 26516159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anti‑angiogenic therapy for normalization of tumor vasculature: A potential effect of Buyang Huanwu decoction on nude mice bearing human hepatocellular carcinoma xenografts with high metastatic potential.
    Min L; Ling W; Hua R; Qi H; Chen S; Wang H; Tang L; Shangguan W
    Mol Med Rep; 2016 Mar; 13(3):2518-26. PubMed ID: 26846752
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MEDI3617, a human anti-angiopoietin 2 monoclonal antibody, inhibits angiogenesis and tumor growth in human tumor xenograft models.
    Leow CC; Coffman K; Inigo I; Breen S; Czapiga M; Soukharev S; Gingles N; Peterson N; Fazenbaker C; Woods R; Jallal B; Ricketts SA; Lavallee T; Coats S; Chang Y
    Int J Oncol; 2012 May; 40(5):1321-30. PubMed ID: 22327175
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Low-dose metronomic chemotherapy with cisplatin: can it suppress angiogenesis in H22 hepatocarcinoma cells?
    Shen FZ; Wang J; Liang J; Mu K; Hou JY; Wang YT
    Int J Exp Pathol; 2010 Feb; 91(1):10-6. PubMed ID: 20096070
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Potent preclinical impact of metronomic low-dose oral topotecan combined with the antiangiogenic drug pazopanib for the treatment of ovarian cancer.
    Hashimoto K; Man S; Xu P; Cruz-Munoz W; Tang T; Kumar R; Kerbel RS
    Mol Cancer Ther; 2010 Apr; 9(4):996-1006. PubMed ID: 20371722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of poly-mechanistic antiangiogenic combinations to enhance cytotoxic therapy response in pancreatic cancer.
    Awasthi N; Zhang C; Ruan W; Schwarz MA; Schwarz RE
    PLoS One; 2012; 7(6):e38477. PubMed ID: 22723862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A metronomic schedule of cyclophosphamide combined with PEGylated liposomal doxorubicin has a highly antitumor effect in an experimental pulmonary metastatic mouse model.
    Shiraga E; Barichello JM; Ishida T; Kiwada H
    Int J Pharm; 2008 Apr; 353(1-2):65-73. PubMed ID: 18155369
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment.
    Kerbel RS
    Cancer J; 2015; 21(4):274-83. PubMed ID: 26222079
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of autophagy enhances anticancer effects of bevacizumab in hepatocarcinoma.
    Guo XL; Li D; Sun K; Wang J; Liu Y; Song JR; Zhao QD; Zhang SS; Deng WJ; Zhao X; Wu MC; Wei LX
    J Mol Med (Berl); 2013 Apr; 91(4):473-83. PubMed ID: 23052483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic efficacy of metronomic chemotherapy with cyclophosphamide and doxorubicin on murine mammary adenocarcinomas.
    Mainetti LE; Rico MJ; Fernández-Zenobi MV; Perroud HA; Roggero EA; Rozados VR; Scharovsky OG
    Ann Oncol; 2013 Sep; 24(9):2310-6. PubMed ID: 23666914
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dual targeting of Bcl-2 and VEGF: a potential strategy to improve therapy for prostate cancer.
    Anai S; Sakamoto N; Sakai Y; Tanaka M; Porvasnik S; Urbanek C; Cao W; Goodison S; Rosser CJ
    Urol Oncol; 2011; 29(4):421-9. PubMed ID: 19576799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.